Could a common ulcer drug prevent deadly bleeding after variceal treatment?
NCT ID NCT07679191
First seen Jul 01, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This trial tests whether applying sucralfate—a medication that forms a protective barrier over wounds—directly onto esophageal ulcers after variceal banding can speed healing and reduce rebleeding. The study includes adults with cirrhosis who have bleeding esophageal varices. Participants receive either standard care plus sucralfate (applied during endoscopy and taken orally for five days) or standard care alone. The goal is to see if sucralfate reduces ulcer size and prevents dangerous rebleeding.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- sucralfate
- What this could lead to
- If it works, this could offer a simple, low-cost way to speed ulcer healing and prevent life-threatening rebleeding after variceal ligation in cirrhosis patients.
- What could go wrong
- This is a small, early-stage trial with 60 participants, so results may not apply broadly. Sucralfate may not significantly reduce bleeding, and some patients may have side effects like constipation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * cirrhotic patients aged ≥ 18 years who accept endoscopy for esophageal variceal bleeding Exclusion Criteria: * no need of endoscopic hemostasis * allergy to sucralfate * other etiology of bleeding than EV bleeding
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal varices bleeding are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.